Vandortuzumab vedotin
Based on 1 Customer Validation
Vandortuzumab vedotin (DSTP 3086S; RG 7450) is a STEAP1-targeted antibody-drug conjugate (ADC). Vandortuzumab vedotin binds specifically to STEAP1, triggers internalization of the conjugate complex, mediates intracellular release of monomethyl auristatin E, inhibits cell division, and induces cell death. Vandortuzumab vedotin exhibits antitumor activity in preclinical prostate cancer xenografts. Vandortuzumab vedotin can be used for the research of metastatic castration-resistant prostate cancer.
For research use only. We do not sell to patients.
- Purity: 99.52%
- CAS No.: 1471985-92-8
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human
STEAP1
ADC (Antibody-Drug Conjugate) is composed of an antibody, a linker, and a cytotoxic payload; it precisely targets and binds to specific antigens on the surface of target cells, and upon internalization, releases the cytotoxic drug to achieve targeted killing of the target cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1471985-92-8
-
Appearance Liquid
-
Color Colorless to light yellow
-
SMILES
[Vandortuzumab vedotin]
-
Synonyms
DSTP 3086S; RG 7450; MSTP2109A
-
Shipping
Shipping with dry ice.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)